Amylyx Pharmaceuticals, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $87.4M | $380.8M | $22.2M | $285,000 |
| Operating income | -$153.3M | -$314.7M | $38.8M | -$201.3M | -$82.7M |
| Cost of revenue | $0 | $6.0M | $25.4M | $3.0M | — |
| Cash from operations | -$123.3M | -$167.6M | $11.9M | -$179.9M | -$74.8M |
| Capital expenditure | $138,000 | $157,000 | $1.2M | $2.5M | $353,000 |
| Free cash flow | -$123.5M | -$167.8M | $10.7M | -$182.4M | -$75.2M |
| Impairments | — | $958,000 | $0 | $0 | $0 |
| Total assets | $332.6M | $193.6M | $517.5M | $391.5M | $105.6M |
| Total liabilities | $27.4M | $28.9M | $84.0M | $50.8M | $17.4M |
Shares outstanding 111.2M · Free float 79.8%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.